Yahoo Finance report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Why SNDL Stock surged +2.42% Today — RQD Quant Desk Flash
SNDL Inc. (SNDL) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SNDL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, SNDL Inc. (NASDAQ: SNDL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.27 (+2.42% 1D, market cap $301.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SNDL ranks #309 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SNDL compare to CGC and USNA in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), SNDL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CGC (Canopy Growth Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $276.0M) and USNA (USANA Health Sciences Inc.) posts a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $264.4M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SNDL?
▼
For SNDL Inc. (SNDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #309 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.2% FCF Margin ($8.4M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a SNDL Turnaround Squeeze
While SNDL currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($1.33) forces dealer call-delta covering toward $2.46.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why SNDL Stock surged +2.42% Today — RQD Quant Desk Flash
SNDL Inc. (SNDL) surged +2.42% to $1.27, trading at 12% of its 52-week range ($1.13 – $2.34). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($1.13 – $2.34) with RSI-14 at 45 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.5% around $1.27 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $8.4M annual free cash flow.
Seeking Alpha report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
SNDL's Q3 sales beat expectations, but margin pressure and persistent cannabis weakness cloud its recovery. Can buybacks and U.S. expansion turn the tide?
SNDL Inc. posted record free cash flow but faces near-term earnings pressure from restructuring and product cuts. Click for this earnings update of SNDL stock.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNDL)
- ✓Walkthrough of SNDL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
SNDL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SNDL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SNDL. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNDL)
1. Head-to-Head Health Care Peer Comparison (SNDL vs. CGC, USNA, OBIO, ACB)
Industry: Medicinal Chemicals and Botanical Products (23 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, SNDL Inc. (SNDL) ranks #309 by composite RQD confidence (47/100, grade D) and #516 by equity capitalization ($301.7M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. ACB currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SNDL at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SNDL
ACTIVE
SNDL Inc. | D | 47/100 | — | — | — | +2.42% | $301.7M | Benchmark Subject |
| CGC Canopy Growth Corporation | D- | 41/100 | — | — | — | +4.34% | $276.0M | /cgc-vs-sndl → |
| USNA USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | +2.87% | $264.4M | /usna-vs-sndl → |
| OBIO Orchestra BioMed Holdings Inc. | E | 34/100 | — | 96.0% | -35.0% | -3.72% | $355.2M | /obio-vs-sndl → |
| ACB Aurora Cannabis Inc. | D+ | 54/100 | — | — | — | +3.94% | $251.5M | /acb-vs-sndl → |
2. SNDL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTSNDL Inc. (SNDL) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $301.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. SNDL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SNDL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, SNDL Inc. (NASDAQ: SNDL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.27 (+2.42% 1D, market cap $301.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SNDL ranks #309 in composite RQD confidence.
How does SNDL compare to CGC and USNA in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), SNDL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CGC (Canopy Growth Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $276.0M) and USNA (USANA Health Sciences Inc.) posts a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $264.4M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SNDL?
For SNDL Inc. (SNDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #309 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SNDL trading relative to its 50-day, 200-day, and 52-week technical levels?
SNDL last traded at $1.27 (+2.42% on volume of 1,233,862 shares), positioning the stock -3.79% below its 50-day simple moving average ($1.32) and -8.63% below its 200-day simple moving average ($1.39). Across its 52-week range of $1.13 to $2.34, SNDL sits at the 11.6% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($1.16 to $1.38).
SNDL — SNDL Inc.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
SNDL Inc. (SNDL) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.27 (+2.42% 1D, market capitalization $301.7M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Sector: Health Care. Industry: Medicinal Chemicals and Botanical Products. Exchange: NASDAQ.. Is a NASDAQ-listed issuer in this industry with a market capitalization of $0.3B. — describes its specific products, customers, or revenue model.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.13 – $2.34 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medicinal Chemicals and Botanical Products (Health Care), SNDL carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can SNDL sustain or expand its — operating margin and — ROIC against Medicinal Chemicals and Botanical Products peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2.34 52-week high?
- Key Question #3: How sensitive is SNDL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
SNDL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for SNDL Inc. (SNDL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering SNDL Inc. (SNDL) market action, institutional positioning, and fundamental catalysts.
SNDL Bull vs. Bear Conversation Board — What's Your Call at $1.27?
Record Q3 free cash flow and expanded capital returns after shareholders rejected consolidation, per the news wire.
The street is overcomplicating SNDL Inc. (SNDL). Record Q3 free cash flow and expanded capital returns after shareholders rejected consolidation, per the news wire.. With an RQD score of 47/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.34.
@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medicinal Chemicals and Botanical Products. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
The RQD rating shows 0% ROIC and 0% FCF yield, with a D grade and a distribution-warning verdict.
I respect the product at SNDL Inc., but the stock at $1.24 is a different story. The RQD rating shows 0% ROIC and 0% FCF yield, with a D grade and a distribution-warning verdict.. FCF yield is 0.0% and RQD sits at 47/100 (D) — why pay up here when you can wait for next quarter's numbers?